Unraveling the Limitations of Wegovy for Weight Loss

Semaglutide (Ozempic/Wegovy), a medication approved for weight loss, does not work for all patients. Some patients do not respond to the drug, while others experience severe side effects that force them to stop taking it. The reasons for non-response are unclear, but it may be related to underlying health conditions or metabolic derangements. Genetic factors, endocrine disorders, and medication interactions need further research to better understand treatment options. Gastrointestinal side effects, such as nausea, vomiting, and diarrhea, are common with semaglutide and can be severe for some patients. Insurance coverage and biases against using medication therapy for obesity can also pose challenges in managing poor reactions. Physicians may consider alternative treatments for patients who do not respond to semaglutide.